Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
Authors
Keywords
Dinaciclib, Chronic lymphocytic leukemia, Relapsed/refractory patients, Cyclin-dependent kinase, Rituximab
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 74, Issue 5, Pages 1057-1064
Publisher
Springer Nature
Online
2014-09-12
DOI
10.1007/s00280-014-2583-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclin-Dependent Kinase Modulators and Cancer Therapy
- (2013) Marialucia Gallorini et al. BIODRUGS
- How I treat patients with relapsed chronic lymphocytic leukaemia
- (2013) Kirsty Cuthill et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials
- (2013) Morag Meriel Griffin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
- (2013) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cyclin-dependent Kinase 9 Links RNA Polymerase II Transcription to Processing of Ribosomal RNA
- (2013) Kaspar Burger et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
- (2013) A Cortelezzi et al. LEUKEMIA
- Emerging drug profile: cyclin-dependent kinase inhibitors
- (2013) James S. Blachly et al. LEUKEMIA & LYMPHOMA
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
- (2013) Brijal M. Desai et al. PLoS One
- Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor
- (2013) W Fu et al. Cell Death & Disease
- Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease
- (2013) Ana E. Rodríguez-Vicente et al. Cancer Genetics
- Cyclin dependent kinases in cancer
- (2012) Miriam Canavese et al. CANCER BIOLOGY & THERAPY
- Rituximab for chronic lymphocytic leukemia
- (2012) Tadeusz Robak EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
- (2011) Georg Feldmann et al. CANCER BIOLOGY & THERAPY
- Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma
- (2011) Christopher Abdullah et al. CELL CYCLE
- The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature
- (2011) Stéphane Lepretre et al. LEUKEMIA & LYMPHOMA
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
- (2011) W. Fu et al. MOLECULAR CANCER THERAPEUTICS
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search